RSS
structurally engineered fatty acid (SEFA)
Dutch biotech secures funds to develop novel treatment for NASH
NorthSea Therapeutics, a Dutch biotech company, has secured €25 million in a Series A funding round, which will be used for the development of icosabutate — a SEFA as a novel, oral approach for the treatment of NASH more
